Argatroban

IUPAC: (2R, 4R ) -1 - [( 2S) -5 - ( Diaminomethylidenamino ) -2 - [[( 3R)- 3-methyl- [ 1,2,3,4- tetrahydroquinolin -8-yl ] sulfonylamino ] pentanoyl ] -4-methyl -piperidin- 2- carboxylic acid

• 74863-84-6
• 141396-28-3 (monohydrate)

B01AE03

Anticoagulants

Thrombin inhibitor

Template: Infobox chemical / molecular formula search available

Argatroban is a drug to prevent blood clotting. The synthetic direct inhibitor of thrombin is in Germany and Austria since 2005 under the name Argatra ® approved for anticoagulation in adult patients with heparin-induced thrombocytopenia a type II (HIT II ) when they require parenteral antithrombotic therapy.

Mechanism of action

Argatroban belongs to the class of direct thrombin inhibitors (DTI ). The substance is a highly effective, monovalent direct thrombin inhibitor which selectively binds to the active catalytic binding site of thrombin. The anticoagulant effect of argatroban based on the reversible inhibition of all the effects of thrombin, including fibrin formation, activation of the coagulation factors V, VII; XII and platelet activation and aggregation. It also inhibits the activation of protein C by thrombin.

Clinical information

Areas of application (indications )

Argatra 100 mg / ml ( argatroban ) concentrate for solution for infusion is indicated for anticoagulation in adult patients with heparin- induced thrombocytopenia type II ( HIT II), which require parenteral antithrombotic therapy.